Novartis AG — Director's Dealing 2019

Nov 6, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Galera Therapeutics, Inc. (GRTX)
CIK: 0001563577
Period of Report: 2019-11-06

Reporting Person: Novartis Bioventures Ltd (10% Owner)
Reporting Person: NOVARTIS AG (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (1779864)		Indirect
Series B Preferred Stock	$		Common Stock (1423891)		Indirect
Series C Preferred Stock	$		Common Stock (89311)		Indirect

Footnotes

F1: Novartis Bioventures Ltd. Is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities.

F2: Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock on a 0.197763-for-one basis at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.